Darotropium Bromide/Vilanterol Trifenatate

达罗溴铵/三苯乙酸维兰特罗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDarotropium Bromide/Vilanterol Trifenatate
Drug Alias Name达罗溴铵/乌美溴铵Vilanterol Trifenatate•Darotropium Bromide达托溴铵/乌美溴铵GSK-233705 + GSK-642444Vilanterol/Darotropium Bromide +[14] 
ClassificationSmall molecules
Mechanisms of ActionMuscarinic acetylcholine receptor M3 antagonistsBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptorMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Darotropium BromideVilanterol Trifenatate
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeN/A
Related LinksN/A